GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (WBO:REGN) » Definitions » Inventories, Raw Materials & Components

Regeneron Pharmaceuticals (WBO:REGN) Inventories, Raw Materials & Components : €724 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Regeneron Pharmaceuticals Inventories, Raw Materials & Components?

Regeneron Pharmaceuticals's inventories, raw materials & components for the quarter that ended in Dec. 2023 was €724 Mil.

Regeneron Pharmaceuticals's quarterly raw materials declined from Jun. 2023 (€751 Mil) to Sep. 2023 (€738 Mil) and declined from Sep. 2023 (€738 Mil) to Dec. 2023 (€724 Mil).

Regeneron Pharmaceuticals's annual raw materials increased from Dec. 2021 (€639 Mil) to Dec. 2022 (€773 Mil) but then declined from Dec. 2022 (€773 Mil) to Dec. 2023 (€724 Mil).


Regeneron Pharmaceuticals Inventories, Raw Materials & Components Historical Data

The historical data trend for Regeneron Pharmaceuticals's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Inventories, Raw Materials & Components Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 194.67 377.63 638.88 772.57 723.79

Regeneron Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 772.57 788.86 750.68 737.70 723.79

Regeneron Pharmaceuticals Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Regeneron Pharmaceuticals (WBO:REGN) Business Description

Industry
Traded in Other Exchanges
Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).